Jessica Flanigan, assistant professor of leadership studies and PPEL, discusses options for lowering the cost for EpiPens with the Winston-Salem Journal Editorial Board.


“Such policies would be morally risky because they can deter innovation and violate the rights of manufacturers who produce life-saving medicines,” Jessica Flanigan, an assistant professor at the University of Richmond, told the Journal. “Instead, public officials should question the FDA’s approval process for generic devices, which has prevented competitors from manufacturing and selling generic EpiPens. Though it may be politically useful to vilify the pharmaceutical industry in the short run, rethinking pharmaceutical regulation is the best way to lower drug prices and help patients in the long run.”


Full article

Associate Professor of Leadership Studies and Philosophy, Politics, Economics and Law
Political Philosophy